US EditionOsteogene to receive up to $1M in matching funding from NJEDA to boost rollout of therapy
Summary by ROI-NJ
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Osteogene to receive up to $1M in matching funding from NJEDA to boost rollout of therapy
Osteogene Tech Corp., a commercial-stage bone regenerative business, said Aug. 19 that it was selected as one of the early-stage technology companies to receive up to $1 million in matching funding from the New Jersey Economic Development Authority’s Angel Match Program. The funds will be used to help accelerate the commercialization of the company’s InRoad technology, an FDA-cleared, engineered bioceramic bone graft that leads to natural bone r…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
